Evolution of the Average Target: Alnylam Pharmaceuticals, Inc.

Evolution of the Target Price: Alnylam Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Alnylam Pharmaceuticals, Inc.

ae.gde5IWkGCRD16vhyTX1zYdTGpMLTVfu4eT1__LEyLCk.9pvXTQZUTWq306gHPBgfBYO3iaaxOpnqJlETkclTWGzO4_B4BUFDRIyokw~67b43a104e236690a56ae781191a12e3
ANALYST RECOMMENDATIONS : CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap... Our Logo
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing MT
JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160 MT
ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... Our Logo
UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating MT
Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing MT
TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating MT
Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating MT
Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating MT
Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating MT
Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating MT
Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating MT
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral... Our Logo
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing MT
HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower... Our Logo
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating MT
More recommendations

Add to a list
Analyst Opinion 4m Revision of opinion Divergence of analysts' opinions Divergence of Target Price Ecart obj. / dr
+10.68%
+20.33%
+15.96%
+12.39%
+26.59%
+9.62%
-6.47%
+9.31%
+16.25%
+19.27%
Average +13.39%
Weighted average by Cap. +14.63%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
234.29USD
Average target price
259.31USD
Spread / Average Target
+10.68%
High Price Target
400.00USD
Spread / Highest target
+70.73%
Low Price Target
159.00USD
Spread / Lowest Target
-32.14%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

HC Wainwright
Chardan Research
Goldman Sachs
Wolfe Research
Morgan Stanley
JPMorgan Chase
RBC Capital Markets
Wells Fargo Securities
UBS
Oppenheimer
Bernstein
Evercore ISI
TD Cowen
BMO Capital
Citigroup
Needham & Co.
Raymond James
Canaccord Genuity
EF Hutton
SVB Securities LLC
Piper Sandler
Berenberg Bank
Jefferies & Co.
Cantor Fitzgerald
Guggenheim
William Blair & Co.
SVB Leerink
Stifel Nicolaus
Chardan
Barclays
Cowen
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
  1. Stock Market
  2. Equities
  3. ALNY Stock
  4. Consensus Alnylam Pharmaceuticals, Inc.